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Abstract
This manuscript studies three differential equation models of the leukemia cell cy-
cle: a population balance model (PBM) using intracellular protein expression levels as
state variables representing phase progress; a delay differential equation model (DDE)
with temporal phase durations as delays; and an ordinary differential equation model
(ODE) of inter-phase progression. In each type of model, global sensitivity analysis de-
termines the most significant parameters while parameter estimation fits experimental
data. In order to compare models based on the output of their structural proper-
ties, an expected behavior was defined, and each model was coupled to a pharma-
cokinetic/pharmacodynamic model of chemotherapy delivery. Results suggest that the
particular cell cycle model chosen highly affects the simulated treatment outcome, given
the same steady state kinetic parameters and drug dosage/scheduling. The manuscript
shows how cell cycle models should be selected according to the complexity, sensitivity
and parameter availability of the application envisioned.
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Introduction
Acute Myeloid Leukemia (AML) is a type of blood cancer characterized by a rapid increase
in immature blood cells with highly proliferative features.1 Chemotherapy treatments rely on
cell duplication cycle phase-specific (CCS) agents, which are specific to cells going through
one of the four phases of the cell duplication cycle.2 The cell cycle is the four phase (G1-S-
G2-M) biological process used by cells to replicate their genetic material and give birth to
new cells.3 The cell cycle is highly regulated by the timed expression of proteins (cyclins)
triggering cell cycle events such as the start of DNA replication (cyclin E, peaking at the end
of G1) or the commencement of mitosis (when the cell physically divides into two daughter
cells - cyclin B, peaking at the end of G2).4 Mathematical models of the cell cycle have
been widely developed both at the mechanistic and descriptive levels.5 Mechanistic models
typically represent protein networks or other biological signals (“high amounts of transition
protein cyclin E will result in likely transition to S phase”) in an effort to explain the
underlying causes for cell growth.6,7 In contrast, descriptive models represent observable
cause-effect phenomena (“one cell gives birth to another cell after 24h”) as an explanation
of the overall system behavior.8–11 Some hybrid mechanistic/descriptive approaches have
arisen, benefiting from the advantages of both (the in-depth insights in mechanistic models,
and the fast computation of key variables in descriptive models). Due to the cell cycle
specificity of most chemotherapeutic drugs, mathematical models are increasingly used to
study and simulate cellular kinetics in response to cancer treatment.12,13 However, choosing
appropriate models is critical for accurate clinical predictions.14 More specifically, models
should be selected according to expected dynamic behavior and parameter identifiability.15,16
Current treatment protocols efficacy is hampered by a lack of patient-specific information
related to drug action and cell cycle kinetics. In AML, bone marrow samples from patients
receiving chemotherapy cannot be collected due to their medical condition and to weaken-
ing treatment effects. Therefore, modeling patient response in silico could provide valuable
insights as a tool for clinicians.17,18 To this end, Pefani et al. 19,20 developed a complete phar-
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macokinetic/pharmacodynamic (PK/PD) model of patient response; the model considered
infusion, transport and degradation of chemotherapeutic drugs inside the body, as well as
drug effects at the point of action (bone marrow). The leukemic cell cycle was represented
as a set of 3 ODEs, one per compartment (cell number totals per phase: G1, S and G2/M).
Global sensitivity analysis revealed that the cell cycle phase durations (τG, τS and τM in
hours) were the most significant parameters for treatment outcomes. However, ODEs do
not describe intra-phase coordinates but an averaged phase behavior. Since cell cycle phase
ODEs (CCP-ODEs) provide only a simplified representation of cell cycle progression, we
hypothesize that the cell cycle model itself, in addition to its parameters, would have an
impact on simulated chemotherapy response. More complex types of models such as popu-
lation balance models (PBM) which are distributed in a second progression-related variable,
or delay differential equation models (DDE) which account for the phase-induced time delay,
could be more suited for the purpose. The cell cycle is typically an oscillating system; its
equilibrium lies at the steady state cell cycle distributions and log-growth. However, when
taken out of the equilibrium, cell fractions undergo a transient state that is characterized
by the oscillatory properties of the specific model chosen.21 Under chemotherapy treatment,
oscillations play a key role as they determine how much room there is for chemotherapy
action (favorable times: target phase highs; unfavorable times: target phase lows).22
In this paper, we present three cell cycle phase models whose parameters can be mea-
sured experimentally. Two of them have been previously proposed: the cell cycle phase PBM
(CCP-PBM) developed by Fuentes-Gar´ı et al. 23 and Garc´ıa Mu¨nzer et al.;24,25 and the Pe-
fani et al. 19 CCP-ODE model. A new cell cycle phase DDE (CCP-DDE) model featuring
phase-specific time delays is presented here as an example of a DDE model with measurable
parameters. DDE cell cycle models have been widely studied by Colijn and Mackey,26,27
considering proliferating and resting cell cycle states, but the parameters required are dif-
ficult to obtain experimentally. All three models (CCP-ODE, CCP-PBM, CCP-DDE) are
compared in: (i) their ability to fit chemotherapy-free experimental data;23 (ii) chemother-
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apy outcomes when embedded in the pharmacokinetic/pharmacodynamic (PK/PD) model
of Pefani et al..19
Model definitions
Development of three differential phase kinetics cell cycle models
Models are presented with increasing levels of complexity (Figure 1, bottom to top). Phase
distributions (percents) are important as they account for oscillatory behavior, in contrast
with phase numbers which increase over time. These distributions can be experimentally
measured by aggregating data from single cell DNA content measurement techniques into
averaged population data.
Figure 1: Model structure in CCP-PBM, CCP-DDE, CCP-ODE with discretization intervals
for CCP-PBM, history vectors and lumped phase compartments for CCP-DDE and lumped
phase compartments only for CCP-ODE.
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An initial approach is to model cell cycle phases with ODEs, with the parameters needed
being the transition rates and the initial cell populations for each phase (refer to Table S2
in Supporting Information for variable and parameter definitions). Pefani et al. 19 give an
example with three compartments (G0/G1, S and G2/M):
dG
dt
= 2 ·M/τM −G/τG or
dG%
dt
= 2 ·M%/τM −G% ·
(
1/τG +
1
T
dT
dt
)
dS
dt
= G/τG − S/τS or
dS%
dt
= G%/τG − S% ·
(
1/τS +
1
T
dT
dt
)
dM
dt
= S/τS −M/τM or
dM%
dt
= S%/τS −M% ·
(
1/τM +
1
T
dT
dt
)
T = G+ S +M
(CCP-ODE)
where G, S and M are the cell numbers in each of G0/G1, S and G2/M phases (in # cells),
T is the total number of cells (in # cells), G%, S% and M% are the phase fractions of total
cells (in %) and τG, τS and τM are the phase durations (in hours) of the G0/G1, S and G2/M
phases respectively. An alternative model accounts for the temporal discrepancy between
cells entering and exiting phases. For this, we developed a new DDE model by introducing
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a time delay equal to phase duration:
dG(t)
dt
= 2 ·M(t− τM)/τM −G(t)/τG or
dG%(t)
dt
= 2 ·M%(t− τM)/τM −G%(t) ·
(
1/τG +
1
T (t)
dT (t)
dt
)
dS(t)
dt
= G(t− τG)/τG − S(t)/τS or
dS%(t)
dt
= G%(t− τG)/τG − S%(t) ·
(
1/τS +
1
T (t)
dT (t)
dt
)
dM(t)
dt
= S(t− τS)/τS −M(t)/τM or
dM%(t)
dt
= S%(t− τS)/τS −M%(t) ·
(
1/τM +
1
T (t)
dT (t)
dt
)
T (t) = G(t) + S(t) +M(t)
(CCP-DDE)
where all variables and parameters are defined as in CCP-ODE and G(t − τG), S(t − τS),
M(t − τM) (in # cells) represent the phase cell number at times t − τG, t − τS and t −
τM respectively (refer to Table S3 in Supporting Information for variable and parameter
definitions). Note that the system is not completely closed (G(t)/τG cells exiting the G
phase versus G(t − τG)/τG cells entering the S phase), however this results in very small
(<3%) variations in total cell number which are transient (total cell number is conserved
at the steady state, see Section F in Supporting Information). An important advantage of
DDEs is that they add a phase coordinate dimension to the system (i.e., cell populations
are not eligible to exit a phase as soon as they enter), so any disturbances in time will be
well captured. Furthermore, CCP-DDE does not require any additional parameters and
maintains a fast computational execution (see Parts A and B in the Supporting Information
for DDE discretization details and initialization equations).
Because phase to phase transition in CCP-DDE systems is based on total phase numbers
at earlier times, not intra-phase cell numbers, properties related to phase progression cannot
be deduced. In order to account for properties varying within each phase, distributed systems
such as PBMs must be used. Previously developed PBMs rely on state variables that are
not always measurable and/or do not maintain fidelity to the underlying biology.8 To make
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this biologically relevant, those properties should be experimentally measurable. In Fuentes-
Gar´ı et al.,23 we presented a CCP-PBM of the cell cycle with cyclins E and B (CE and CB,
proteins related to phase progression; normalized % expression) as state variables for G0/G1
and G2/M, where their concentration actively increases throughout the phase, and DNA
content (in DNA units) as state variable for S phase (where DNA replication occurs):
∂G (CE, t)
∂t
+
∂
(
G (CE, t) · dCEdt
)
∂CE
= −rG→S (CE) ·G (CE, t) (1)
∂S (DNA, t)
∂t
+
∂
(
S (DNA, t) · dDNA
dt
)
∂DNA
= 0 (2)
∂M (CB, t)
∂t
+
∂
(
M (CB, t) · dCBdt
)
∂CB
= −rM→G (CB) ·M (CB, t) (3)
and the boundary conditions are written:
rG ·G (CE = CE,min, t) = 2 ·
∫ CB,max
CB,min
rM→G (CB) ·M (CB, t) dCB (4)
rS · S (DNA = 1, t) =
∫ CE,max
CE,min
rG→S (CE) ·G (CE, t) dCE (5)
rM ·M (CB = CB,min, t) = rS · S (DNA = 2, t) (6)
Growth rates (rG = dCE/dt, rS = dDNA/dt and rM = dCB/dt; h
−1) correlate phase
progression to its state variable and are constant (see definition in Appendix C); transition
rates (rG→S(CE) and rM→G(CB); h−1) account for the transition probability according to
the state variable level (see Part C and Table S4 in the Supporting Information for details).
The model was discretized in cyclin E (resulting in nE bins with indices e ∈ {1, . . . , nE}),
in cyclin B (resulting in nB bins with indices b ∈ {1, . . . , nB}) and in DNA (resulting in nD
bins with indices d ∈ {1, . . . , nD}) and validated for 3 leukemia cell lines (K-562, MEC-1,
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MOLT-4) experimentally:
dGe
dt
= (1− δ(e− 1)) ·Ge−1 · rG · νE −Ge · νE · (rG + rG→S, e)
+δ(e− 1) · 2 ·
nB∑
b=1
Mb · rM→G, b · νB
dGe,G%
dt
= (1− δ(e− 1)) ·Ge−1, G% · rG · νE −Ge,G% ·
(
rG · νE + rG→S, e · νE + dGdt · 1G
)
+δ(e− 1) · 2
G%
·
nB∑
b=1
Mb, T% · rM→G, b · νB ∀ e ∈ {1, . . . , nE}
dSd
dt
= (1− δ(d− 1)) · Sd−1 · rS · νD − Sd · rS · νD + δ(d− 1) ·
nE∑
e=1
Ge · rG→S, e · νE
dSd, S%
dt
= (1− δ(d− 1)) · Sd−1, S% · rS · νD − Sd, S% ·
(
rS · νD + dSdt · 1S
)
+δ(d− 1) · 1
S%
·
nE∑
e=1
Ge, T% · rG→S, e · νE ∀ d ∈ {1, . . . , nD}
dMb
dt
= (1− δ(b− 1)) ·Mb−1 · rM · νB −Mb · νB · (rM + rM→G, b) + δ(b− 1) · SnD · rS · νD
dMb,M%
dt
= (1− δ(b− 1)) ·Mb−1,M% · rM · νB −Mb,M% ·
(
rM · νB + rM→G, b · νB + dMdt · 1M
)
+δ(b− 1) · 1
M%
· SnD, T% · rS · νD ∀ b ∈ {1, . . . , nB}
with: G =
nE∑
e=1
Ge, S =
nD∑
d=1
Sd, and M =
nB∑
b=1
Mb;
and Ge,G% = Ge/G, Sd, S% = Sd/S, and Mb,M% = Mb/M
And the total being:
T (t) =
nE∑
e=1
Ge +
nD∑
d=1
Sd +
nB∑
b=1
Mb
with: Ge, T% = Ge/T , Sd, T% = Sd/T , and Mb, T% = Mb/T
(CCP-PBM)
The parameters νE, νD and νB represent the conversion factor from bins to cyclin expression
and are a result of the discretization method, in G0/G1, S and G2/M phases. The terms
rG→S, e and rM→G, b (h−1) account for the discretized transition rates in each of the G0/G1
(e bins) or G2/M (b bins) phases. δ(x) takes the values 1 for x = 0 and 0 for any other value
of x. A summary of model parameters and how to obtain them is shown in Table 1.
9
Table 1: Model parameters and experimental methods needed to obtain them (the model
source is clearly stated, otherwise all models use that specific parameter).
Parameter Lab Lab Data
protocol time processing
Cell cycle chase:
τG, τS, τM In vitro culture (> 24 h) 40-60 h 10-15 h
Frequent sampling
GSS,%, SSS,%, MSS,% No culturing needed
G0,%, S0,%, M0,% Initial time point only 2-3 h 10 min
Fast sample preparation
µ (CCP-ODE) 2 samples needed
γ (CCP-DDE) either in vitro culture 5-10 h 10-15 min
α(CCP-PBM) or in vivo blood sample
CCP-PBM: σB, σE, 1 sample needed
CB,min, CE,min, DNA, cyclin E&B labelling 10-15 h 1-2 h
CB,max, CE,max segregate 2 subpopulations
Solution of the steady state problem
The system’s steady state in population balance models is frequently studied for nucleation
and crystal growth processes.28 In the cell duplication context, cell cycle phases may reach
steady state with respect to the percentage of cells in each phase (G%, S%, M%) but not in
the phases themselves (G, S, M) as the absolute count will increase over time as a result
of doubling. Cell cycle models usually oscillate initially when they are taken out of their
equilibrium cell cycle distribution (transient state) and progressively reach steady state as
they approach phase equilibrium. If these models are initialized at equilibrium, they should
not oscillate. The equilibrium cell cycle phase distributions are determined by setting their
derivative to zero (see Part D in the Supporting Information for an extended derivation).
For CCP-ODEs, the equilibrium cell cycle phase distributions are given by the real root
of Eq (30) in the SI for G%, SS and by Eq (27) and (28) in the SI for M%, SS and S%, SS
respectively. The log-growth coefficient is calculated as:
dT
dt
1
T
=
1
τM
·M%, SS = µ (7)
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Similarly, Eq (43)-(45) in the SI represent the steady state cell cycle distribution for CCP-
DDEs, with log-growth coefficient:
dT
dt
· 1
T
=
1
τM
·MSS,% ·
(
2 · e−γ·τM − 1)+ 1
τG
·GSS,% ·
(
e−γ·τG − 1)+ 1
τS
·SSS,% ·
(
e−γ·τS − 1) = γ
(8)
Finally, the steady state cell cycle distribution (intra-phase as well as phase totals if summed)
for CCP-PBM is given by Eq (76)-(78) in SI, with the log-growth coefficient calculated as:
dT
dt
· 1
T
=
nB∑
b=1
Mb, SS, T% · rM→G, b · νB = α (9)
Embedding CC models into a previously developed PK/PD model
Pefani et al. 19 developed a PK/PD model simulating patient response to chemotherapy de-
livery with two common drugs, cytarabine (Ara-C) and daunorubicin (DNR). Ara-C acts
by in terfering with DNA duplication (in S phase only).29 DNR attacks S phase cells by
DNA intercalation but also G1 cells by inhibition of macromolecular biosynthesis.30 The
treatment prescribed by the physician is used as an input variable consisting of drug dose
and administration route. Parameters adjustable on a case-by-case basis included height and
weight, age and cell cycle times (Figure 2). Pharmacokinetics (PK) considers the transport
and transformation the drug undergoes once it reaches the blood streams, and in turn the
relevant organs which absorb it at different rates.31 Mass balances are performed in each of
these organs, giving the drug concentration profiles, which are the main input for pharma-
codynamics (PD). In the PD model, the drug effect on cells is computed according to cell
cycle kinetics. Since chemotherapy acts only during specific cell cycle phases, detailed cell
cycle equations modeling the point of drug action are needed (as confirmed by their global
sensitivity analysis).
The drug effect term is applied differently in each model. The effects occur only in the G
and S compartments and are accounted for through kd,G and kd, S death rates, respectively.
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Figure 2: Schematic of the interactions between PK, PD and cell cycle components of the
Pefani et al. model, together with input of patient data.
In the original CCP-ODE model, they are included directly into each equation as:
dG
dt
= 2 ·M/τM −G/τG − kD,G ·G
dS
dt
= G/τG − S/τS − kD,S · S
dM
dt
= S/τS −M/τM
(CCP-ODE-PD)
When moving to CCP-DDE, the temporal delay has to be considered: cells in those phases
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are subject to chemotherapy for as long as the delay lasts.
dG(t)
dt
= 2 ·M(t− τM)/τM −G(t)/τG − kD,G(t) ·G(t)
dS(t)
dt
= G∗(τG)/τG − S(t)/τS − kD,S(t) · S(t)
dM(t)
dt
= S∗(τS)/τS −M(t)/τM where:
dG∗(t∗G)
dt∗G
= −kd,G ·G∗(t∗G) with G∗(t∗G = 0) = G(t− τG)
or: G∗(τG) = G(t− τG) · e−kd,G·τG
dS∗(t∗S)
dt∗S
= −kd, S · S∗(t∗S) with S∗(t∗S = 0) = S(t− τS)
or: S∗(τS) = S(t− τS) · e−kd, S ·τS
(CCP-DDE-PD)
Finally, the drug is applied similarly to CCP-PBM, in a homogeneous manner throughout
the relevant phases:
dGe
dt
= (1− δ(e− 1)) ·Ge−1 · rG · νE −Ge · (rG · νE + rG→S, e · νE + kd,G)
+2δ(e− 1) ·
nB∑
b=1
Mb · rM→G, b · νB ∀ e ∈ {1, . . . , nE}
dSd
dt
= (1− δ(d− 1)) · Sd−1 · rS · νD − Sd · (rS · νD + kd, S) + δ(d− 1) ·
nE∑
e=1
Ge · rG→S, e · νE
∀ d ∈ {1, . . . , nD}
dMb
dt
= (1− δ(b− 1)) ·Mb−1 · rM · νB −Mb · νB · (rM + rM→G, b) + δ(b− 1) · SnD · rS · νD
∀ b ∈ {1, . . . , nB}
(CCP-PBM-PD)
Note that the percentage of cells killed at a given time point is the same in all three
models, however CCP-DDE-PD and CCP-PBM-PD incorporate drug effects (due to phase
distribution in either time or space) in a time-cumulative manner while CCP-ODE-PD only
account for instantaneous effects of that particular dose.
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Results and discussion
The objective of this paper is to answer the question: are the models under study
suitable for the application envisioned? To address this question, we will first deal
with the case where no treatment is applied (exponential growth conditions) and in the
second part the chemotherapy will be incorporated. Several aspects are to be considered
under both cases.
Analysis under exponential growth conditions
Satisfying short-term kinetics
Defining the transient state requires identifying the significant parameters for each model
short-term (for the first cell cycle) and finding their values through parameter estimation
with experimental data.
What parameters are needed short-term? Global sensitivity analysis (GSA) was per-
formed for all three models by varying the parameters they have in common (phase durations)
40% around their nominal (experimental) values simultaneously following Sobol’s method
(Section E in SI), and observing the effect on the model output for phase fractions. For each
model, the number of intervals (model evaluations) required to obtain accurate estimates is
found to be different: 5,000 intervals for CCP-ODE, 2,000 intervals in CCP-DDE and 20,000
intervals for CCP-PBM. The sensitivity indexes were compared for the three phases (Figure
3) over one cell cycle (22h) at 0h, 1h and 5h intervals subsequently. It was confirmed that
phase times were significant, especially in their own (cell exit) and the following phases (cell
entrance). For CCP-ODEs, sensitivity indices become approximately constant after 10h,
while CCP-DDEs’ sensitivity indices do not follow any particular pattern and CCP-PBMs
seem to keep their indices relatively constant and with a lower value.
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Figure 3: GSA sensitivity indices of phase fractions G%, S% and M% to phase duration
parameters τG, τS and τM in CCP-PBM, CCP-DDEs, CCP-ODEs. The x-axis represents
culture time in hours; the y-axis represents the sensitivity indices of each phase fraction: G%
(top), S% (middle) and M% (bottom). The indexes are gathered by sensitive phase (rows)
and by parameter analyzed (τG, τS and τM in each model, initial distribution (PBM) and
phase variability (PBM), columns). (MEC-1).
Can the models fit experimental data? To compare the ability of all three models to
fit experimental data, we used the synchronous experimental data of Fuentes-Gar´ı et al. 23
together with the CCP-PBM simulation results reported. Results for all three models can
be seen in Figure 4, and parameter estimates (Table 2) for CCP-ODE and CCP-DDE were
fitted computationally using the parameter estimation module of gPROMS (Process Systems
Enterprise), which utilizes the max log likelihood algorithm (parameters for CCP-PBM were
extracted from experiments23). The CCP-PBM and CCP-DDE presented here can capture
synchronous oscillatory behavior while the CCP-ODE fail to account for this intra-phase
heterogeneity, resulting in a lack of fit of this particular model, as confirmed by the residual
sum of squares (Table 3). Linear stability analysis (LSA) is a model analysis technique that
determines systems of equations’ dynamic behavior prior to any simulation, by assessing the
stability of its steady states.21 LSA was performed on CCP-ODE revealing that a decaying
amplitude oscillatory behavior is expected for the whole working parameter range (see Part E
in the Supporting Information for details). Spatial (such as protein expression in CCP-PBM)
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or temporal (such as the delay history in CCP-DDE) distributions easily facilitate capturing
oscillations computationally. The fitted model parameters are always lower for CCP-DDE
and higher for CCP-PBM. For CCP-ODE, the fitted parameters do not follow any specific
patterns, but in general are closer to the ones of CCP-PBM. Overall difference between
values outside the experimental range is 2h for CCP-PBM, 10.3h for CCP-DDE and 4.7h
in CCP-ODE (refer to Table 2). Therefore, the CCP-PBM cell cycle times are consistently
the closest to the ones measured experimentally, which together with the model’s structure
strengthens the CCP-PBM’s ability to capture the underlying biology in a more meaningful
way.
Figure 4: Comparison of experimental phase percents in 3 leukemia cell lines (K-562, MEC-1,
MOLT-4) with simulation results for CCP-ODE, CCP-DDE, CCP-PBM.
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Table 2: Phase time parameters estimated in each of the three models as compared to the
ones obtained experimentally.
Cell line CC phase time CCP-PBM CCP-DDE CCP-ODE Exp. measurements
τG 9.0h 4.4h 5.8h 6 ± 2h
K-562 τS 10.0h 6.6h 12.0h 10 ± 2h
τM 5.0h 2.7h 3.9h 4 ± 2h
τG 8.5h 4.6h 8.4h 7 ± 2h
MEC-1 τS 7.5h 2.9h 5.6h 8.5 ± 2h
τM 3.0h 2.6h 4.7h 5 ± 2h
τG 12.0h 5.0h 4.2h 10 ± 2h
MOLT-4 τS 15.0h 8.5h 10.3h 12 ± 2h
τM 2.0h 1.4h 1.1h 2 ± 2h
In summary, CCP-ODE do not capture the short-term oscillatory behavior required;
CCP-DDE capture it well but its parameters do not correlate to the underlying biology;
finally, CCP-PBM produce both the oscillations required and parameters in the range of the
ones found experimentally.
Table 3: Residual sum of squares (RSS) for the parameter estimation in each model, for each
cell line.
Cell line CCP-PBM CCP-DDE CCP-ODE
K-562 0.1017 0.1038 0.6527
MEC-1 0.1046 0.0461 0.3550
MOLT-4 0.0488 0.0468 0.3906
Satisfying short-term and long-term kinetics
The previous section showed that transient kinetics for 1 cell cycle is successfully captured by
both CCP-DDE and CCP-PBM, albeit with parameter discrepancies compared to the actual
experimental measurements for CCP-DDE. For a short-term scenario (1 cell cycle), cell cycle
durations sufficiently simulate phase kinetics; alternatively, steady state parameters may be
used to calculate them (see Part D in the Supporting Information). Phase variabilities can be
set at their nominal level since they are not significant in the short-term. If protein kinetics
is also required, then minima and thresholds for each of them have to be determined for the
CCP-PBM. This was further confirmed by the GSA results.23 However, transient kinetics
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provides only partial information, as steady state behavior represents a major component of
leukemia growth in the resting periods between chemotherapy cycles.
Defining the oscillatory behavior required The oscillatory behavior is characterized
by its time to steady state, value at the steady state and oscillation amplitude (all observable
experimentally, Figure 5), for each of the phases. It is worth mentioning that previous steady
state analyses performed on one compartment models have determined analytically the rate
at which oscillations decay over time. The exponential rate at which oscillations decay
has not been found in models similar to CCP-PBM with three distributed compartments.32
However, numerical simulations can be run for specific cases and relevant parameters such
as the amplitude of the oscillations or the time to steady state can be obtained.
The equations reproduced here are for G phase but equations for S and M would be
obtained similarly. The time to steady state (TSS,G) is defined as the time it takes for
oscillations to dampen to a level lower than a certain tolerance , or:
|GSS,% −Gpeak,%(TSS,G)|
GSS,%
<  (10)
As a standard,  = 1% will be used in the simulations subsequently, since the experimen-
tal error is always greater than 1% and does not allow identifying oscillations under that
threshold.
The value at steady state is calculated as discussed in the Model Definitions Section,
while the amplitude of the oscillations (AG) represents the deviation from the steady state
value at each of the peaks:
AG =
|GSS,% −Gpeak,%(t)|
GSS,%
(11)
In order to satisfy oscillations at all three levels mathematically, three degrees of freedom
per phase are required.
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Can short-term and long-term kinetics be concurrently satisfied? For CCP-DDE
and CCP-ODE, all parameters have already been utilized for the initial dynamics; they do
not have enough degrees of freedom to validate both the transient state and the steady
state and will have a significant limitation tackling long-term dynamic problems. Adjusting
oscillatory behavior at all dimensions (TSS,G, TSS, S, TSS,M , GSS,%, SSS,%, MSS,%, AG, AS
and AM) is only possible in CCP-PBM. Up to now, only 2 parameters per phase have been
exploited: phase times and initial conditions. However, there is a parameter that did not
appear significant in the first few hours in PBM, but has an important influence in those
oscillatory properties later on: the standard deviation for the transitions in G and M. In
fact, it is the interplay between phase duration and variability in the transition that defines
the CCP-PBM’s oscillatory characteristics. Different values of τG and σE were tested (all
else being equal) based on MEC-1 parameters; results are shown in Figure 5. Increasing
variability decreases TSS, GSS and AG (after the first oscillation), while resulting in a more
pronounced first oscillation. Conversely, increasing τG does not have such a significant impact
on TSS, with increased variation in GSS, and a clear difference in AG for the first oscillation
(moderately later). Finally, higher deviations from GSS in the initial phase percents result
in longer TSS and larger AG, but no effect is seen in the actual value GSS (as expected since
the initial conditions do not appear in the steady state equations).
What parameters are needed long-term? To accurately define the parameters needed
long term, we performed a GSA on the CCP-PBM for 500h, varying the phase times (τG, τS
and τM) and phase variabilities (σE and σB). The initial conditions appear to be significant
only in the beginning of the transient state; as a result, they will not be included in this
analysis which focusses on the steady state. The sensitivity of the phase fraction amplitudes
(AG, AS and AM) was monitored over time, while the sensitivity of the steady state variables
(GSS,%, SSS,% and α) and the time to steady state (TSS) were recorded at the end of the
500h period (when all dynamic simulations had reached steady state).
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The GSA results reported in Figure 6 reveal that G2/M phase parameters are not very
relevant to the overall oscillatory behavior (it is the shortest phase by hours). Next, we see
that τS is very significant for AG and AM initially but decreases with time, as τG increases
mildly. τG is equally significant for AS and decreases only slightly with time. The effect of
variables from previous phases on the entrance of cells is confirmed long-term (for G0/G1,
it is τS that becomes relevant since G2/M is very short). Additionally, σE becomes more
significant in the long-term (although its sensitivity index (SI) stays below the one of τG).
Therefore, the amplitude of the oscillations depends partly on the variability in G phase,
which was also observed in cell automata models33 and experimentally.34 To summarize,
the amplitude of the oscillations is controlled by phase durations at earlier times and by a
balance of phase durations and phase variability at later times. For the steady state values,
only τG and τS appear significant (sensitivity index ≥ 0.1). Surprisingly, for TSS, only τS is
important.
Can the necessary parameters be measured?
The necessary parameters for CCP-DDE and CCP-ODE are the initial conditions and either
the steady state distribution + log-growth coefficient (“steady state parameters”) or the
phase times (“dynamic parameters”). CCP-PBM will require additionally the transition
variabilities for G and M (Figure 7).
Obtaining dynamic parameters experimentally requires labelling a cellular subset (S
phase cells which incorporate the DNA label during the duplication process) in culture
and tracking its phase-to-phase movement over one cell cycle; this is because natural asyn-
chrony makes it impossible to watch cells move in a unified manner between phases. State
variable levels (cyclins E and B, and DNA content) are monitored in parallel in order to
seamlessly validate CCP-PBM’s phase progression features. Tracking typically occurs over
the course of one cycle (20-40hrs for cell lines) and needs a minimum sampling frequency
to shape phase oscillations (2-4hrs). Cell cycle times (τG, τS and τM) are extracted directly
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Figure 5: Capturing oscillatory properties: a. experimental evolution of G0/G1 % (MOLT-4
cell line) over 40h, vs CCP-PBM output under different scenario: b. varying the standard
deviation of the transition probability; c. varying the phase time; or d. varying the initial
phase fraction (all else being equal).
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Figure 6: Global sensitivity analysis of CCP-PBM oscillations over 500h (MEC-1), varying
phase times and variabilities. Outputs monitored are the amplitude of the oscillations in
each phase (top 3 panels) and the steady state variables (at 500h).
Figure 7: Experimental protocols to carry out in order to obtain each of the parameter sets.
“Dynamic parameters” require culturing cells for some period of time, while “steady state
parameters” can be obtained directly from any samples.
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from experimental data, and then the model can be validated against the dynamic phase
evolution.
In contrast, steady state parameters, as their name suggests, need only selected static data
to be determined. For the steady state phase distribution (GSS,%, SSS,%, MSS,%), a single
sample (in exponential growth conditions) is sufficient, as the experimental measurement
itself gives directly the phase fractions. For the log-growth parameter (α, γ or µ, depending
on the model), at least two samples from different times (taken from the same unchanged
culture) are needed. However, increased sample numbers give a higher accuracy for both
parameter types. Typically, these measurements can be obtained in parallel with others (no
need for cell cycle-specific experiments) and during convenient times (not limited to specific
times within one cell cycle). As a downside, the data obtained is insufficient to reliably
validate the simulations.
In vitro, any of the two parameter sets can be obtained, albeit with significantly different
experimental effort. Because both parameter sets are linked through the steady state equa-
tions (Part D of the Supporting Information), they can be used interchangeably in silico
from a theoretical point of view.
Analysis under chemotherapy treatment
Setting the grounds for comparison
We have established that CCP-ODE and CCP-DDE do not have the required degrees of
freedom per phase (2) to capture the oscillatory features required (3). In order to continue
with the comparison, a choice must be made: either to satisfy the steady-state constraints
or the transient behavior. If we choose to satisfy dynamic constraints (lacking degrees of
freedom), only short term, transient kinetics will be well captured. On the contrary, if steady
state constraints are satisfied, total cell kinetics and cell cycle distribution will be correctly
simulated long-term, at the expense of initial dynamics. The decision should be taken based
on the application envisaged: since the purpose of cell cycle models is to capture the response
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to chemotherapy (long-term process that starts at steady state, highly dependent on total
cell number), ensuring an accurate steady state response is critical. Based on this choice,
and for CCP-PBM/CCP-DDE/CCP-ODE comparisons to be fair, the total kinetics (so that
the cell number is equal) and the cell cycle distribution (so that the percentage of cells likely
to be affected when chemotherapy starts) will have to be equal at steady state.
Equaling α = γ = µ (Eq (7)-(9)) and two of the phase fractions (GSS,%,CCP-ODE =
GSS,%,CCP-DDE = GSS,%,CCP-PBM; SSS,%,CCP-ODE = SSS,%,CCP-DDE = SSS,%,CCP-PBM), cell
cycle times can be converted from one system (CCP-ODE, CCP-DDE, CCP-PBM) to an-
other. Given the cell cycle times in the CCP-DDE system (which is the most complex to
solve practically), all other cell cycle times can be obtained through this process of equaling
the total growth rate and the phase distributions at steady state (see sample parameter
conversion in Table 4).
Table 4: Cell cycle times converted from CCP-DDE to CCP-PBM and CCP-ODE for the
steady state conditions chosen (GSS,% = 79.3%, SSS% = 16.0%, MSS% = 4.8%, α = µ =
γ = 0.0157h−1)
CCP-PBM CCP-DDEs CCP-ODEs
τG 36.8h 16.6h 41h
τS 8.9h 4.7h 10h
τM 3.4h 1.5h 3h
How sensitive is the model to chemotherapy effects?
We have seen that both CCP-PBM and CCP-DDE are capable of fitting synchronous experi-
mental data, a fact that is critical in modeling chemotherapy due to its phase-specific action
(G1 and S phase) and subsequent aggregation of cells into synchronized populations.8 In
this section, each model will be embedded into a PK/PD model of chemotherapy delivery in
leukemia20 and tested for its sensitivity to chemotherapy (as captured by the chemotherapy
drug effect parameters kD,S and kD,G for S and G1 phases respectively in CCP-ODE-PD,
CCP-DDE-PD and CCP-PBM-PD).
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An example male patient that is 167.5cm tall and 79.3kg in weight, 80 years old, receiving
a chemotherapy treatment of 100 mg/m2 Ara-C (12h infusion twice a day for 10 days) and
50 mg/m2 DNR (pulse dose on days 1, 3 and 5) is selected for a PK/PD comparison. The
latter are the input parameters for the PK model.
Comparing total cell evolution over the treatment period in the three models (Figure 8),
we observe that the CCP-ODE-PD sensitivity to chemotherapy is effectively lower due to its
inherent tendency to allow the passage of cells from phase to phase (Figure 9). Its absence
of intra-phase distribution results in a fraction of the cells in S always eligible to move to the
next phase. Conversely, CCP-DDE-PD and CCP-PBM-PD allow for cells to be distributed
Figure 8: Comparison of cell cycle distribution (top 3 panels) and total cell number(bottom
right) under chemotherapy treatment (bottom left panel) in: CCP-ODE-PD, CCP-DDE-PD,
CCP-PBM-PD under equivalent growth kinetics (converted from CCP-DDE-PD to equiva-
lent parameters in CCP-ODE-PD and CCP-PBM-PD - see equal cell cycle distribution and
total growth kinetics after 10 days of treatment)
in each phase (temporally and spatially, respectively), creating a downward trend in the
percentage of cells in the distribution. This is in accordance with the intuitive fact that
subjecting cells to drug effects throughout a phase will make it less likely to find cells at the
end of the phase. As a result, fewer cells are found in CCP-DDE-PD and CCP-PBM-PD
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in G2/M (Figure 8). CCP-ODE-PD reach higher G2/M phase percents, representing the
higher fraction of S phase cells coming in. The percentage of G2/M cells becomes critical
due to its impact on total cell duplication (if cells do not reach mitosis, duplication cannot
occur).
Drug sensitivity is reflected in the slope (logarithmic) of the decrease in the total leukemia
cells: moderate for CCP-ODE-PD, intermediate for CCP-DDE-PD and steep for CCP-
PBM. CCP-DDE-PD response seems to be halfway between CCP-PBM-PD and CCP-ODE-
PD, in that cell totals are 2-3 orders of magnitude above CCP-PBM-PD and below CCP-
ODE-PD, while the cell cycle distribution oscillatory behavior can be broadly said to be
a combination of CCP-ODE-PD (peak timings) and CCP-PBM-PD (central value). Note
that CCP-PBM-PD and CCP-DDE-PD fluctuate approximately around the steady state
value for S and G0/G1 fractions during treatment, while CCP-ODE-PD remain at a high
for G%, compensated by a low S%. Oscillations post-treatment are the most sustained
for CCP-PBM-PD, while CCP-DDE-PD take 1-2 cell cycles to stabilize and CCP-ODE-
PD immediately reach steady state. Further, when changing the σ/τ balance in G0/G1
and G2/M for the CCP-PBM-PD (always maintaining the same steady state), oscillations
decrease in amplitude when increasing σ (Figure 10) and may converge to a shape similar
to the CCP-DDE-PD oscillations (see σ = 50%). Similarly, totals become lower at the end
of treatment with decreasing σ.
Cojoracu and Agur 35 obtained a similar result related to increased resistance of higher
standard deviations of phase durations. Even with the highest variability tested (σ = 50%),
the total number at the end of treatment (day 10) is lower than the one for CCP-DDE-
PD (despite the cycle fractions being very similar). The simple fact that the CCP-PBM-
PD’s oscillatory behavior can be adjusted allows for the possibility of taking into account
these discrepancies in treatment response. We admit CCP-DDE-PD could benefit from
adding phase duration variability (or decoupling the transition parameters from the delays),
requiring an extra parameter per phase and thus allowing increased flexibility in fitting
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Figure 9: Model mechanics under chemotherapy effects. Observe that total cell kill at time
t is the same, however the drug effect bin after bin (for CCP-PBM-PD, or time after time,
for CCP-DDE-PD) results in decreasing percentages of the population that initially entered
the phase reaching the final bins (for CCP-PBM-PD, or times for CCP-DDE-PD).
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oscillatory patterns. Nevertheless, the superiority of CCP-PBM-PD lies in its biological
relevance, which allows direct parameter measurement and validation. Significant differences
have been observed in model behavior especially when all efforts have been made to make
model conditions as close as possible.
Figure 10: Comparison of cell cycle distribution (top, bottom left) and total cell number
(bottom right) under same conditions as Figure 8 in CCP-PBM-PD (change in σ% and τ
according to same steady state) and CCP-DDE-PD (black dashed line) under equivalent
growth kinetics
Discussion
Three different models representing cell cycle kinetics were presented here and analyzed for
their ability to capture oscillations and their response to chemotherapy under the same steady
state behavior. When fitted to experimental data, only CCP-DDE and CCP-PBM performed
well, with CCP-PBM having the most biologically relevant parameters (additionally to ac-
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curately predicting intracellular protein expression as reported in Fuentes-Gar´ı et al. 23). A
procedure for converting a set of in vitro measured model parameters to a different set of
model parameters that define model dynamics equally well is then presented. An important
advantage of this is potentially more efficient experimentation. A second advantage of in-
terconvertibility in parameter sets was homogeneity and univocal definition with respect to
expected behavior under PK/PD conditions. Each of the models was then embedded in a
PK/PD model of chemotherapy for AML and a patient case was run. Throughout the treat-
ment, CCP-ODE had the highest percent of cells in the G2/M phase and the lowest amount
of cell kill, which was explained by their inability to capture intra-phase distributions, letting
cells transition to the next phase as soon as they have entered (thus escaping continuous
phase exposure to the chemotherapy effect). Conversely, CCP-PBM and CCP-DDE set a
spatial or temporal restriction to the eligibility of cells to transition to the next phase, and
subject those cells for a minimum phase time to the effect of chemotherapy (leading to a
lower percent of G2/M cells and a higher cell kill at the end of the treatment).
Cell cycle model selection has a critical impact on predicted chemotherapy response.
Current standards in PK/PD rely on cell cycle models that are not always accurate enough
and that have not necessarily been validated. For more advanced use of these models, such
as for optimal control of chemotherapy delivery36–38 and drug scheduling,10 a precise rep-
resentation of cell cycle processes becomes critical (deconvoluting total growth kinetics into
cell cycle phases, capturing intra-phase progression). Cell cycle models for chemotherapy
optimisation should be carefully selected and suited to their application. A first and critical
consideration is whether the model parameters are relevant in vitro/in vivo and are measur-
able39 (or can be converted into a new set of parameters that are). A second consideration
is whether both the dynamic (transient) and steady state behaviors obtained are accurate in
representing the underlying biology and clinical response (sensitivity to drugs). Finally, the
trade-off between model complexity and matching the required degrees of freedom exhibited
by the system needs to be taken into account.
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The CCP-PBM model presented here provides a good trade-off between capturing more
complex pathway and protein kinetics, which are normally reported in mechanistic models
only, and maintaining a computationally efficient solution representing global cell kinetics, of
which the CCP-ODE discussed is a clear example. Importantly, treatment personalization
requires defining measurable parameters representing patient heterogeneity.40 Our CCP-
PBM is seamlessly linked to experimentally measurable parameters that have been reported
to be highly heterogeneous among AML patients.41,42 Due to its distributed structure, our
CCP-PBM captures cell cycle oscillatory complexity to a great extent, despite being an
aggregate model. Moving to more detailed, experimentally validated models is clearly the
way forward.
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Figure captions
Figure 1: Model structure in CCP-PBM, CCP-DDE, CCP-ODE with discretization in-
tervals for CCP-PBM, history vectors and lumped phase compartments for CCP-DDE and
lumped phase compartments only for CCP-ODE.
Figure 2: Schematic of the interactions between PK, PD and cell cycle components of
the Pefani et al. model, together with input of patient data.
Figure 3: GSA sensitivity indices of phase fractions G%, S% and M% to phase duration
parameters τG, τS and τM in CCP-PBM, CCP-DDEs, CCP-ODEs. The x-axis represents
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culture time in hours; the y-axis represents the sensitivity indices of each phase fraction: G%
(top), S% (middle) and M% (bottom). The indexes are gathered by sensitive phase (rows)
and by parameter analyzed (τG, τS and τM in each model, columns). (MEC-1).
Figure 4: Comparison of experimental phase percents in 3 leukemia cell lines (K-562,
MEC-1, MOLT-4) with simulation results for CCP-ODE, CCP-DDE, CCP-PBM.
Figure 5: Capturing oscillatory properties: a. experimental evolution of G0/G1 %
(MOLT-4 cell line) over 40h, vs CCP-PBM output under different scenario: b. varying the
standard deviation of the transition probability; c. varying the phase time; or d. varying
the initial phase fraction (all else being equal).
Figure 6: Global sensitivity analysis of CCP-PBM oscillations over 500h (MEC-1), vary-
ing phase times and variabilities. Outputs monitored are the amplitude of the oscillations
in each phase (top 3 panels) and the steady state variables (at 500h).
Figure 7: Experimental protocols to carry out in order to obtain each of the parameter
sets. “Dynamic parameters” require culturing cells for some period of time, while “steady
state parameters” can be obtained directly from any samples.
Figure 8: Comparison of cell cycle distribution (top 3 panels) and total cell num-
ber(bottom right) under chemotherapy treatment (bottom left panel) in: CCP-ODE-PD,
CCP-DDE-PD, CCP-PBM-PD under equivalent growth kinetics (converted from CCP-DDE-
PD to equivalent parameters in CCP-ODE-PD and CCP-PBM-PD - see equal cell cycle
distribution and total growth kinetics after 10 days of treatment).
Figure 9: Model mechanics under chemotherapy effects. Observe that total cell kill at
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time t is the same, however the drug effect bin after bin (for CCP-PBM-PD, or time after
time, for CCP-DDE-PD) results in decreasing percentages of the population that initially
entered the phase reaching the final bins (for CCP-PBM-PD, or times for CCP-DDE-PD).
Figure 10: Comparison of cell cycle distribution (top, bottom left) and total cell num-
ber (bottom right) under same conditions as Figure 8 in CCP-PBM-PD (change in σ% and
τ according to same steady state) and CCP-DDE-PD (black dashed line) under equivalent
growth kinetics.
Table captions
Table 1: Model parameters and experimental methods needed to obtain them (the model
source is clearly stated, otherwise all models use that specific parameter).
Table 2: Phase time parameters estimated in each of the three models as compared to
the ones obtained experimentally.
Table 3: Residual sum of squares (RSS) for the parameter estimation in each model, for
each cell line.
Table 4: Cell cycle times converted from CCP-DDE to CCP-PBM and CCP-ODE
for the steady state conditions chosen (GSS,% = 79.3%, SSS% = 16.0%, MSS% = 4.8%,
α = µ = γ = 0.0157h−1).
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